Cover
Vol. 1 No. 1 (2022)

Published: December 21, 2022

Pages: 1-5

Original Article

Possibility of infection with COVID-19 in vaccinated Iraqi people

Haitham Mahmood Kadhim 1 Feryal Hashim Rada 2 Zainab Mohammed Ali 3 Muna Haider Mohammed 2 Saja Alah Mahdi 2 Juman Jasem Mohammed 2 Hassanein Ahmed Tareq 2
1Department of Pharmacology and Toxicology, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
2Department of Pharmacutics, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
3Students of Pharmacy College, Al-Nahrain University, Baghdad, Iraq
History
  • Received: October 12, 2022
  • Accepted: November 10, 2022
  • Available Online: December 21, 2022

Abstract

Objective: As the pandemic effect of viral infection with COVID-19 caused dreadful from death in worldwide, thereafter many vaccines manufactured against it. The aim of this study is to explore the acceptability of anti-COVID-19 vaccine in Iraqi population. Methods: An online survey conducted in February 2022 among current vaccinated people that included 308 participants (108 males and 200 females) aged (18-66) years. The questionnaire involved questions about the vaccine type ,vaccine dose number, presence of infection after vaccination, symptom of infection after vaccination, period of infection appearance after vaccination, duration of infection presence after vaccination. Results: The upper percent of questionnaire database reported that 68% of people take Pfizer vaccine, 84 % of people take twice dose of vaccine. Moreover, 68 % of people not infected after taking vaccine, symptom that appear after vaccination 15% mild to moderate. While, the period of infection appearance after vaccination was 25% more than one month, and the duration of infection presence after vaccination was 22% about one week. Conclusion: The outcomes of this study showed the important role of anti- COVID-19 vaccine in constricted the spreading effect of COVID-19 infection for a reasonable level.

Keywords

References

  1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–423. doi: 10.1002/jmv.25681
  2. Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. doi: 10.3390/v12020135.
  3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease COVID-19 outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433.
  4. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO; 2015.
  5. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
  6. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: A comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9:1–29.
  7. Xiao Z, Xie X, Guo W, Luo Z, Liao J, Wen F, Zhou Q, Han L, Zheng T. Examining the incubation period distributions of COVID-19 on Chinese patients with different travel histories. J Infect Dev Ctries. 2020;14:323–327. doi: 10.3855/jidc.12718.
  8. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med. 2020;172:577–582. doi: 10.7326/M20-0504.
  9. Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: From SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104. doi: 10.1186/s12929-020-00695-2.
  10. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–71.
  11. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022;22(2):183–95.
  12. Acharya CB, Schrom J, Mitchell AM, Coil DA, Marquez C, Rojas S, et al. No significant difference in viral load between vaccinated and unvaccinated, asymptomatic and symptomatic groups infected with SARS-CoV-2 delta variant. MedRxiv. 2021 Jan 1.
  13. Rada FH. Assessment of pyrazino-pyrimidine compound and some inflammatory biomarkers in patients with type 2 diabetes. Int J Pharm Sci Res. 2017;8(6):2691–5. doi: 10.13040/IJPSR.0975-8232.8(6).2691-95.
  14. Rada FH. Oxidative stress and some inflammatory biomarkers in patients with coronary heart disease. Eur J Pharm Med Res. 2018;5:9–12.
  15. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report-97. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-COVID-19.pdf
  16. World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines. Available from: https://www.who.int/who-documents-detail-redirect/who-target-product-profiles-for-COVID-19-vaccines. Accessed June 16, 2020.
  17. US Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine. FDA; 2020. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-COVID-19/pfizer-biontech-COVID-19-vaccine. Accessed December 23, 2020.
  18. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease (COVID-19) outbreaks in the United States. 2020 Nov 30 [revised 2021 Jan 2]. doi: 10.1101/2020.11.27.20240051.